Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C

Liver Transplantation

Volumn 15, Issue 8, 2009, Pages 948-955

  Fernández, Inmaculada ^a   Ulloa, Esperanza ^a   Colina, Francisco ^a   Abradelo, Manuel ^a   Jiménez, Carlos ^a   Gimeno, Alberto ^a   Meneu, Juan Carlos ^a   Lumbreras, Carlos ^a   Solís Herruzo, José Antonio ^a   Moreno, Enrique ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REBELOL; RIBAVIRIN; TACROLIMUS; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BILE DUCT DISEASE; BILIRUBIN BLOOD LEVEL; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; REFRACTORY ANEMIA; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION;

EID: 69949100741     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21780     Document Type: Article

References (39)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
2. Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-256.
3. Berenguer M, Prieto M, Rayon J, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-858.
4. European Liver Transplant Registry. Registry for the European Liver Transplant Association. Available at: http://www.eltr.org. Accessed February 2009.
5. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin: an open-label series. Transplantation 2004;77:190-194.
6. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669-674.
7. Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transplantation 2004;78:1303-1307.
8. Moreno JM, Gonzalez E, Graña E, Botella A, Peinado C, Poza JL, et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 2005;37:2207-2208.
9. Berenguer M, Palau A, Fernández A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risk associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067-1076.
10. Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy in the treatment of recurrent hepatitis C after liver transplantation. Liver Transpl 2006;12:1805-1812.
11. Carrión JA, Navasa M, García-Retortillo M, García-Pagán JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation. Gastroenterology 2007;132:1746-1756.
12. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679-687.
13. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995;22:1084-1089.
14. Gadano AC, Mosnier JF, Durand F, Martinot-Peignoux M, Marcellin P, Degott C, et al. Alpha-interferon induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995;59:1627-1629.
15. Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994;330:1160-1161.
16. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005;41:289-298.
17. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
18. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
19. Demetris A, Adams D, Bellamy C, and an International Panel. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. Hepatology 2000;31:792-799.
20. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
21. Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C recurrence. Gut 2003;52:283-287.
22. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004;10:199-207.
23. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459-465.
24. Wright HG, Combs C, Kim M, Ferrell L, Bachetti P, Aschner N, et al. Interferon alfa therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20: 773-779.
25. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-504.
26. Samuel D, Bizollon T, Feray C, Roche B, Si Ahmed SN, Lemonnier C, et al. Interferon- 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-650.
27. Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003;35:3042-3044.
28. Castells L, Vargas V, Allende H, Bilbao I, Lázaro JL, Margarit C, et al. Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53-59.
29. Stanca CM, Fiel MI, Kontorinis N, Agarwal K, Emre S, Schiano TD. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007;84:180-186.
30. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004;10:859-867.
31. Walter T, Dumotier J, Guillaud O, Hervieu V, Paliard P, Scoazec JY, et al. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007;7: 177-184.
32. Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003;9:1159-1165.
33. Watashi K, Hijikata M, Hosaka M, Yamagi M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
34. US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331: 1110-1115.
35. European FK506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994;334:423-428.
36. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-29.
37. Charlton MR, Seaberg EC, Wiesner RH, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
38. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-3493.
39. Quaglia AF, Del Vecchio Blanco G, Greaves R, Burroughs AK, Dhillon AP. Development of ductopaenic liver allograft rejection includes a "hepatitic" phase prior to duct loss. J Hepatol 2000; 33:773-780.